

# Caterina Ilari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4799522/publications.pdf>

Version: 2024-02-01

325  
papers

9,593  
citations

66234

42  
h-index

48187

88  
g-index

329  
all docs

329  
docs citations

329  
times ranked

11392  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	5.1	1,031
2	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	13.9	949
3	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	1.3	407
4	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	0.6	395
5	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	0.6	336
6	Targeting Mutant <i>BRAF</i> in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
7	Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	13.9	279
8	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
9	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
10	Diffuse large B-cell lymphoma genotyping on the liquid biopsy. <i>Blood</i> , 2017, 129, 1947-1957.	0.6	183
11	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015, 126, 1925-1929.	0.6	154
12	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	0.6	147
13	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	1.7	121
14	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. <i>Annals of Oncology</i> , 2010, 21, 1870-1876.	0.6	119
15	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	1.5	110
16	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	1.3	106
17	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	2.6	105
18	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104

#	ARTICLE	IF	CITATIONS
19	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
20	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. <i>Frontiers in Oncology</i> , 2019, 9, 726.	1.3	85
21	The KrÄ¼ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	3.3	84
22	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	1.7	72
23	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <i>Haematologica</i> , 2013, 98, 675-685.	1.7	65
24	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomibâ€“dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. <i>Leukemia</i> , 2017, 31, 997-1000.	3.3	64
25	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
26	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	0.6	63
27	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 2053-2060.	1.7	60
28	Comparative analysis between RQâ€“PCR and digitalâ€“dropletâ€“PCR of immunoglobulin/Tâ€“cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 541-549.	1.2	59
29	Bleeding phenotype and correlation with factor XI (FXI) activity in congenital <i>FXI</i> deficiency: results of a retrospective study from a single centre. <i>Haemophilia</i> , 2015, 21, 496-501.	1.0	58
30	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	3.3	57
31	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. <i>Haematologica</i> , 2014, 99, 1248-1254.	1.7	57
32	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.	3.3	57
33	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
34	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
35	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	2.0	56
36	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55

#	ARTICLE	IF	CITATIONS
37	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
38	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	0.8	53
39	BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?. <i>Cancer</i> , 2019, 125, 194-204.	2.0	51
40	BCR-ABL1-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	0.6	49
41	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	1.7	49
42	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
43	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018, 132, 405-412.	0.6	46
44	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1473-1484.	2.0	45
45	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	1.7	44
46	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	2.8	43
47	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.4	41
48	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019, 9, 689.	1.3	41
49	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 20520-20531.	0.8	40
50	Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 588-596.	1.2	39
51	HIF-1 $\alpha$ is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
52	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 818-826.	1.5	37
53	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	0.8	36
54	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. <i>Haematologica</i> , 2015, 100, e10-e13.	1.7	35

#	ARTICLE	IF	CITATIONS
55	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. <i>Oncotarget</i> , 2015, 6, 42569-42574.	0.8	35
56	Clinical impact of small subclones harboring <i>NOTCH1</i> , <i>SF3B1</i> or <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e135-e138.	1.7	34
57	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. <i>OncoImmunology</i> , 2016, 5, e1041701.	2.1	34
58	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	1.2	34
59	Management of adult Ph-positive acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 406-413.	0.9	33
60	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
61	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	0.6	33
62	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	1.7	33
63	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
64	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	0.8	32
65	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e534-e543.	2.2	31
66	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	2.9	31
67	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	1.7	31
68	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 2399-2411.	13.9	31
69	Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. <i>Leukemia Research</i> , 2015, 39, 1382-1388.	0.4	30
70	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
71	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
72	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019, 134, 740-740.	0.6	30

#	ARTICLE	IF	CITATIONS
73	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	1.6	28
74	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018, 32, 1778-1786.	3.3	28
75	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBP $\beta$ . <i>Leukemia</i> , 2015, 29, 2442-2445.	3.3	27
76	Philadelphia $\beta$ -positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID $\beta$ 19 pandemic: a Campus ALL study. <i>British Journal of Haematology</i> , 2020, 190, e3-e5.	1.2	27
77	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	2.0	26
78	Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 826-843.	1.2	26
79	Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. <i>Leukemia Research</i> , 2016, 44, 53-60.	0.4	25
80	Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID $\beta$ 19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	1.2	25
81	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2838-2840.	0.6	24
82	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197.	0.4	23
83	Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome $\beta$ -Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 812-820.	3.2	23
84	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. <i>Blood</i> , 2014, 123, 3677-3679.	0.6	22
85	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	0.8	21
86	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	2.0	21
87	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	0.8	20
88	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <i>Leukemia and Lymphoma</i> , 2016, 57, 2685-2688.	0.6	20
89	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 529-535.	2.0	20
90	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. <i>Leukemia</i> , 2018, 32, 1807-1810.	3.3	20

#	ARTICLE	IF	CITATIONS
91	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	0.8	20
92	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 4193-4199.	1.0	20
93	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2021, 5, e543.	1.2	20
94	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
95	Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018, 20, 23.	1.8	19
96	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	0.6	19
97	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018, 103, 1889-1898.	1.7	19
98	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	0.8	19
99	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	0.8	19
100	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 951-958.	1.7	18
101	Comparison between the CLL-IPI and the Barcelona prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37.	2.0	18
102	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808.	0.8	18
103	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 629-639.	1.2	18
104	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	1.2	18
105	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017, 57, 65-71.	0.4	17
106	Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019, 37, 652-654.	0.8	17
107	THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 110-111.	0.8	17
108	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17

#	ARTICLE	IF	CITATIONS
109	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
110	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
111	Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 577-582.	1.5	16
112	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2016, 30, 1615-1619.	3.3	16
113	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 2552-2559.	3.3	16
114	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019044.	0.5	16
115	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	1.7	16
116	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. <i>Leukemia Research</i> , 2019, 87, 106233.	0.4	16
117	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 249-258.	1.2	16
118	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
119	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
120	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
121	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021, 138, 2290-2293.	0.6	15
122	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, E661-E664.	2.0	14
123	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	1.0	14
124	<sc>TPO</sc>â€<sc>RA</sc>s in <sc>pITP</sc>: description of a case series and analysis of predictive factors for response. <i>European Journal of Haematology</i> , 2017, 98, 242-249.	1.1	14
125	Venetoclax in CLL patients who progress after B-Cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	1.2	14
126	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	0.8	14



#	ARTICLE	IF	CITATIONS
127	COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome. <i>Acta Haematologica</i> , 2020, 143, 574-582.	0.7	14
128	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
129	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
130	Changes in the Treatment Landscape for Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 273-274.	13.9	13
131	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	0.8	13
132	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	0.8	13
133	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 7586-7596.	0.8	13
134	Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with <i>Ebf1-Pdgfr</i> fusion transcript. <i>Leukemia and Lymphoma</i> , 2020, 61, 469-472.	0.6	12
135	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
136	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. <i>Hematological Oncology</i> , 2021, 39, 680-686.	0.8	12
137	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	0.8	12
138	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	1.7	12
139	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolmmunology</i> , 2018, 7, e1341032.	2.1	11
140	Another step forward in the 20-year history of <i>IGHV</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 219-221.	1.7	11
141	Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 81-87.	1.0	11
142	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416.	0.8	11
143	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 828-836.	0.6	11
144	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11

#	ARTICLE	IF	CITATIONS
145	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013, 122, 405-405.	0.6	11
146	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 797-797.	0.6	11
147	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 601-611.	1.0	10
148	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019, 98, 1891-1904.	0.8	10
149	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	0.8	10
150	<i>IL7R</i> overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 829-832.	0.6	10
151	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
152	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103163.	2.0	10
153	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
154	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <i>Oncotarget</i> , 2017, 8, 25455-25468.	0.8	10
155	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	1.3	10
156	Clinical relevance of silent red blood cell autoantibodies. <i>Haematologica</i> , 2017, 102, e473-e475.	1.7	9
157	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	0.5	9
158	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	0.8	9
159	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
160	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
161	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 804714.	1.3	9
162	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1640-1647.	0.6	8

#	ARTICLE	IF	CITATIONS
163	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
164	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. <i>Cancer Immunology Research</i> , 2018, 6, 1110-1119.	1.6	8
165	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019, 98, 1919-1925.	0.8	8
166	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020, 34, 441-450.	3.3	8
167	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020, 61, 536-545.	0.6	8
168	The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020, 13, 1067-1072.	1.0	8
169	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
170	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
171	The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. <i>British Journal of Haematology</i> , 2021, 194, 78-82.	1.2	8
172	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. <i>Blood</i> , 2016, 128, 1214-1214.	0.6	8
173	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017, 92, E668-E670.	2.0	7
174	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
175	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
176	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. <i>Blood</i> , 2010, 116, 871-871.	0.6	7
177	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. <i>Haematologica</i> , 2021, 106, 1500-1503.	1.7	7
178	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	1.2	7
179	Acute lymphoblastic leukemia: age and biology. <i>Mental Illness</i> , 2011, 3, 2.	0.8	6
180	Management of elderly and unfit patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 1165-1175.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. <i>Leukemia and Lymphoma</i> , 2017, 58, 999-1001.	0.6	6
182	Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1224-1233.	0.6	6
183	RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019024.	0.5	6
184	Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020, 13, 1311-1318.	1.0	6
185	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
186	ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e346-e349.	1.2	6
187	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 755-757.	0.6	6
188	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021, 193, 325-338.	1.2	6
189	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the FBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	3.3	6
190	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
191	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	0.6	6
192	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
193	Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. <i>Haematologica</i> , 2022, 107, 2356-2364.	1.7	6
194	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. <i>Haematologica</i> , 2022, 107, 1955-1959.	1.7	6
195	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809.	0.8	5
196	Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience. <i>Acta Haematologica</i> , 2018, 140, 105-111.	0.7	5
197	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
198	Aplastic Anemia and Good Syndrome in a Heavily Treated Stage IV Thymoma Patient: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2019, 2019, 1-6.	0.3	5

#	ARTICLE	IF	CITATIONS
199	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e101-e105.	1.2	5
200	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
201	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
202	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.4	4
203	Cytomegalovirus in Bone Marrow Cells Correlates with Cytomegalovirus in Peripheral Blood Leukocytes. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2183-2185.	1.8	4
204	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. <i>Haematologica</i> , 2018, 103, e138-e140.	1.7	4
205	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , 2018, 32, 543-546.	3.3	4
206	Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. <i>Annals of Hematology</i> , 2021, 100, 2117-2119.	0.8	4
207	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027.	0.6	4
208	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	0.8	4
209	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients – a 25-year Italian experience. <i>British Journal of Haematology</i> , 2021, 195, 278-283.	1.2	4
210	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	0.6	4
211	Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2111-2111.	0.6	4
212	Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 334-337.	1.7	4
213	Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. <i>BMC Infectious Diseases</i> , 2021, 21, 1079.	1.3	4
214	Does MRD have a role in the management of iNHL?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 320-330.	0.9	4
215	The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. <i>Leukemia Supplements</i> , 2012, 1, S26-S28.	0.1	3
216	Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. <i>European Journal of Internal Medicine</i> , 2018, 58, 22-27.	1.0	3

#	ARTICLE	IF	CITATIONS
217	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584.	1.1	3
218	Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. <i>Leukemia and Lymphoma</i> , 2019, 60, 274-276.	0.6	3
219	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
220	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704.	0.8	3
221	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+ bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
222	Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience. <i>Acta Haematologica</i> , 2021, , 1-5.	0.7	3
223	Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 281-294.	1.0	3
224	Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center. <i>Leukemia and Lymphoma</i> , 2021, 62, 3430-3439.	0.6	3
225	Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter, Report from the Campus ALL/Gimema Network. <i>Blood</i> , 2018, 132, 658-658.	0.6	3
226	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018, 132, 4954-4954.	0.6	3
227	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
228	Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome. <i>Blood</i> , 2016, 128, 2959-2959.	0.6	3
229	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
230	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	3
231	Caring for patients with haematological malignancies. <i>Lancet Oncology</i> , The, 2011, 12, 928-929.	5.1	2
232	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2.	2.0	2
233	Enteropathy-associated T-cell lymphoma in childhood: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2015, 56, 2743-2746.	0.6	2
234	Life-threatening autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura: successful selective splenic artery embolization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016020.	0.5	2

#	ARTICLE	IF	CITATIONS
235	The antileukemic potential of natural killer cells. <i>Immunotherapy</i> , 2016, 8, 425-434.	1.0	2
236	Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. <i>Leukemia and Lymphoma</i> , 2016, 57, 1716-1718.	0.6	2
237	Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2018, 59, 2715-2718.	0.6	2
238	Incidence of Clinically Significant ( $\geq 10$ g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019, 42, 660-664.	0.8	2
239	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPO-RA. <i>Haemophilia</i> , 2019, 25, e288-e290.	1.0	2
240	Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. <i>HIV Medicine</i> , 2020, 21, e7.	1.0	2
241	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777.	0.8	2
242	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025.	0.6	2
243	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 320-327.	1.0	2
244	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	0.6	2
245	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 2888-2888.	0.6	2
246	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	0.6	2
247	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
248	Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1003-1015.	1.3	2
249	Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle income countries. <i>British Journal of Haematology</i> , 2022, 196, 849-863.	1.2	2
250	A broad and integrated diagnostic work-up for a modern management of Acute Lymphoblastic Leukemia (ALL). <i>Hematology</i> , 2005, 10, 55-62.	0.7	1
251	Reappraising the timing of transplant for indolent non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2016, 9, 951-964.	1.0	1
252	Management of CLL in the elderly. <i>Annals of Oncology</i> , 2017, 28, 200-204.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e217-e219.	1.2	1
254	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. <i>Acta Haematologica</i> , 2019, 142, 185-186.	0.7	1
255	Platelet activation and multidrug resistance protein-4 expression in children and adolescents with different subtypes of primary thrombocythemia. <i>Haematologica</i> , 2020, 105, e65-e67.	1.7	1
256	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	0.8	1
257	A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	1
258	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	1.7	1
259	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.	0.6	1
260	Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome. <i>Blood</i> , 2018, 132, 4256-4256.	0.6	1
261	Incidence and Predictors of Early Treatment-Related Mortality In Pediatric Acute Lymphoblastic Leukemia In Baghdad (Iraq). <i>Blood</i> , 2010, 116, 2132-2132.	0.6	1
262	Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,. <i>Blood</i> , 2011, 118, 3564-3564.	0.6	1
263	Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7125-TPS7125.	0.8	1
264	Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7025-7025.	0.8	1
265	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 295-295.	0.6	1
266	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019, 134, 2624-2624.	0.6	1
267	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	0.6	1
268	â€œMiroâ€•Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20073-e20073.	0.8	1
269	Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study. <i>Blood</i> , 2021, 138, 3408-3408.	0.6	1
270	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1



#	ARTICLE	IF	CITATIONS
271	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. <i>Training/Validation Study. Blood</i> , 2020, 136, 31-32.	0.6	1
272	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	1
273	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. <i>the Richter Syndrome Scoring System. Blood</i> , 2020, 136, 33-34.	0.6	1
274	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 838-843.	0.4	1
275	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
276	714 CONTROLLED - RELEASE (CR) OXYCODONE FOR THE TREATMENT OF IATROGENIC NEUROPATHIC PAIN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. <i>European Journal of Pain</i> , 2006, 10, S186b-S186.	1.4	0
277	The European Hematology Association: strengthening hematology in Europe and beyond. <i>Expert Review of Hematology</i> , 2011, 4, 133-136.	1.0	0
278	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic workup. <i>American Journal of Hematology</i> , 2016, 91, E319-20.	2.0	0
279	AB0150...Increased eryptosis levels in primary antiphospholipid syndrome patients. , 2017, , .		0
280	Current and future therapeutic approaches for the treatment of follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 931-941.	1.1	0
281	Response to Comment by Amato T. <i>et al.</i> . <i>Haematologica</i> , 2019, 104, e541-e541.	1.7	0
282	First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure". <i>Lancet Haematology</i> , the, 2020, 7, e182-e183.	2.2	0
283	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
284	Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We Go. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 257-258.	1.0	0
285	Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. <i>Blood</i> , 2004, 104, 1897-1897.	0.6	0
286	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. <i>Blood</i> , 2004, 104, 1119-1119.	0.6	0
287	Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in <i>BCR-ABL1</i> -positive acute lymphoblastic leukemia (ALL) patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 7049-7049.	0.8	0
288	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. <i>The Gimema Experience.. Blood</i> , 2009, 114, 1019-1019.	0.6	0

#	ARTICLE	IF	CITATIONS
289	CRLF2/JAK Signaling in Adult and Pediatric Acute Lymphoblastic Leukemia Is Highly Similar to BCR/ABL.. Blood, 2009, 114, 3461-3461.	0.6	0
290	BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. Journal of Clinical Oncology, 2012, 30, 6531-6531.	0.8	0
291	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1780-1780.	0.6	0
292	Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients. Blood, 2013, 122, 2026-2026.	0.6	0
293	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. Blood, 2013, 122, 5045-5045.	0.6	0
294	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. Blood, 2013, 122, 1336-1336.	0.6	0
295	Splenectomy Is Still a Valid Option For Splenic Marginal Zone Lymphoma. Blood, 2013, 122, 5129-5129.	0.6	0
296	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 3687-3687.	0.6	0
297	Clinical Features and Prognostic Factors in Solitary Plasmacytoma: A Single Center Retrospective Study. Blood, 2014, 124, 3455-3455.	0.6	0
298	Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2014, 124, 1326-1326.	0.6	0
299	Bendamustine and Dexamethasone Is an Effective Salvage Regimen for Patient with Advanced Multiple Myeloma in a Home Care Unit Program. Blood, 2014, 124, 5753-5753.	0.6	0
300	Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience. Blood, 2015, 126, 2788-2788.	0.6	0
301	Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma. Blood, 2016, 128, 5308-5308.	0.6	0
302	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	0.6	0
303	HIF-1 $\alpha$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	0.6	0
304	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. Blood, 2016, 128, 5589-5589.	0.6	0
305	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€™A two-cohort phase II study.. Journal of Clinical Oncology, 2017, 35, TPS7567-TPS7567.	0.8	0
306	AB0163â€™...Increased eryptosis levels in erythrocytes treated with antibodies from aps patients: eryptosis as new actor in aps pathogenesis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
307	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746.	0.6	0
308	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
309	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518.	0.6	0
310	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741.	0.6	0
311	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 1844-1844.	0.6	0
312	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. <i>Blood</i> , 2018, 132, 5634-5634.	0.6	0
313	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464.	0.6	0
314	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	0.6	0
315	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	0.6	0
316	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021, 138, 704-704.	0.6	0
317	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
318	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
319	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
320	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
321	Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects. <i>Blood</i> , 2020, 136, 37-37.	0.6	0
322	Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	0.6	0
323	IgVH mutations in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2005, 90, 434-5.	1.7	0
324	Management of adult patients with Philadelphia positive acute lymphoblastic leukemia. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2013, 54, 1828-37.	0.5	0

#	ARTICLE	IF	CITATIONS
325	Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients.. Blood Transfusion, 2022, , .	0.3	0